Tagraxofusp (Elzonris) is a more recent example of a truncated DT immunotoxin fused with human interleukin 3 (IL-3) which received FDA approval for the treatment of blastic plasmacytoid dendritic cell neoplasm (BPDCN) in 2018 [9]. This evidence concerns the gene IL3 and CD4+/CD56+ hematodermic neoplasm.